Derek spent $180 a month on supplements. Meticulous about it, too — a spreadsheet tracked his stack. Zinc, magnesium, vitamin D, ashwagandha, creatine, and, since his favorite podcast host mentioned it in an episode, fadogia agrestis. He’d read that it could raise testosterone by stimulating luteinizing hormone. He’d seen the before-and-after claims in the forums. He was all in.
When he mentioned it to his doctor at his annual physical, she’d never heard of it. She didn’t know enough to call it dangerous or safe, which he read as a green light. When he asked the supplement store employee, he got a confident nod and a pitch for the 90-capsule option. When he searched for clinical trials, he found exactly one relevant animal study and a lot of blog posts citing that same study in ways that ranged from cautiously optimistic to aggressively oversold.
Derek’s story is a near-perfect illustration of a dynamic that’s become pervasive in the men’s health optimization space: a single study, in rats, conducted in Nigeria in 2005, absorbed into the content industrial complex, laundered through podcasts with massive audiences, and repackaged as actionable supplementation advice for millions of men who have no way of knowing how thin the evidence actually is.
What Fadogia Agrestis Is
Fadogia agrestis is a shrub native to Nigeria and parts of West Africa. Traditionally, aqueous extracts of the stem have been used in Nigerian folk medicine as an aphrodisiac and for treating conditions like malaria, fever, and erectile dysfunction. It belongs to the family Rubiaceae, the same botanical family as coffee.
The plant has a long history of traditional use, worth acknowledging up front. Traditional medicine has historically been a reasonably reliable starting point for pharmacological investigation — many effective drugs were developed from traditional remedies by identifying and isolating the active compounds, understanding mechanisms, and establishing safety and efficacy through clinical research.
The key phrase there is “starting point.” Traditional use signals: this is worth investigating. It does not signal: this is safe and effective. The investigation is the part that tells you whether the traditional use was pointing at something real.
For fadogia agrestis, the investigation has barely begun. As of this writing, the peer-reviewed evidence base on this compound consists primarily of one animal study on testosterone effects, a handful of related rodent studies on aphrodisiac properties and toxicity, and no published randomized controlled trials in human subjects. That’s it. That’s the entire scientific foundation a booming supplement category has been built on.
The Single Study: What Yakubu 2005 Actually Found
- This was a five-day rat study. Rat physiology differs from human physiology in important ways, particularly in hormonal metabolism. Results in rats frequently don’t translate to humans.
- The study wasn’t designed to establish safety. The short duration means it can say nothing meaningful about what happens over weeks, months, or years of use.
- A follow-up study by some of the same authors found testicular toxicity. At higher doses and longer durations, fadogia agrestis extract caused histopathological changes in rat testes — structural damage to the tissue that produces testosterone. The same mechanism that might acutely stimulate testosterone production may, with sustained exposure, damage the machinery doing the producing.
- The study has never been replicated in a controlled human trial. Zero. Not a pilot study. Not an observational cohort. Nothing.
The study most commonly cited in the fadogia agrestis literature is Yakubu, Akanji, and Oladiji (2005), published in the Asian Journal of Andrology. The researchers gave aqueous stem extracts of fadogia agrestis to male rats at doses of 18, 36, and 100 mg/kg body weight per day for five days. They then measured serum testosterone, testicular cholesterol, and certain sex organ weights.
The findings: testosterone levels increased in a dose-dependent manner. The highest dose group showed the largest increase. The mechanism proposed by the authors was increased conversion of cholesterol to testosterone in the testes, with possible effects on luteinizing hormone signaling.
What the promoters emphasize: testosterone went up. What they tend to skip over:
To be clear about what this means: the entire testosterone-boosting case for fadogia agrestis rests on a five-day rat study. The safety case — or rather, the safety concern — rests on follow-up rodent research showing testicular damage at higher doses and longer durations.
Picture a friend announcing they’re going to start taking a drug that raised testosterone in rats for five days but also showed signs of damaging the rat testes at higher doses, with zero human studies behind it. Most people would tell them to wait. That’s the situation, in plain terms.
The Huberman Effect and the Responsibility of Reach
Andrew Huberman is a Stanford neuroscientist with one of the most popular health and science podcasts on the planet. Intelligent, genuinely knowledgeable, and he’s done real public good translating neuroscience research into practical protocols. He’s also someone whose platform is large enough that a single mention of a supplement can generate millions of dollars in sales for that category within days.
Huberman has discussed fadogia agrestis on his podcast in the context of testosterone optimization. Generally measured in his language, acknowledging uncertainty — typically more careful than the downstream content creators who pick up his mentions and run with them. But “measured acknowledgment of uncertainty” from a Stanford professor on a podcast with tens of millions of subscribers still functions very differently in the market than it would in a peer-reviewed journal.
The problem isn’t that Huberman mentioned fadogia agrestis. The problem is the information cascade: podcast mention → supplement company marketing (“as discussed by [expert]”) → forum posts (“X takes this”) → blog articles citing the forums → YouTube videos citing the blogs → Derek’s supplement stack. By the time it reaches Derek, the single rat study has been laundered through so many layers of repackaging that it arrives wearing the clothes of established science.
This dynamic isn’t unique to Huberman, not unique to fadogia agrestis, and not really anyone’s deliberate fault. It’s a structural feature of health content economics: uncertainty is boring, confidence is shareable, and novel compounds are exciting. The incentives all push toward overstatement.
“The distance between ‘a rat study showed promising results’ and ‘thousands of men are taking this supplement daily’ is just a podcast episode and a content marketing budget.”
The Actual Proposed Mechanism
Understanding why fadogia agrestis is theoretically interesting — not just marketable — requires understanding how testosterone production is regulated.
Testosterone production in men is governed by the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus releases gonadotropin-releasing hormone (GnRH), which signals the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH travels to the Leydig cells in the testes and stimulates them to produce testosterone. Negative feedback loops — testosterone and estrogen feeding back to the hypothalamus and pituitary — regulate the whole system.
The hypothesis for fadogia agrestis is that it contains compounds — possibly saponins or alkaloids in the plant — that either stimulate LH production or directly stimulate the Leydig cells to convert cholesterol to testosterone, bypassing part of the feedback loop.
Biologically plausible. There are other natural compounds that work similarly — certain compounds in ashwagandha appear to influence LH signaling and cortisol pathways in ways that modestly support testosterone. The mechanism itself isn’t the problem with fadogia agrestis. The problem is that the mechanism in humans hasn’t been studied, and the doses required to produce the effect in rats, when extrapolated to human body weight, may sit in a range that causes the testicular damage observed in the higher-dose rodent studies.
Here’s the crux of it. You can’t cherry-pick the testosterone effect from the toxicity data and only worry about one. They appear to sit on the same dose-response curve.
The Novel Compound Risk Assessment Framework
1. Evidence Quality Score. What’s the highest-quality study available? Rank from 1 (anecdote/traditional use only) to 5 (multiple randomized controlled trials with long-term follow-up in humans). Fadogia agrestis scores 1-2: animal studies with no human RCT data. Ashwagandha scores 3-4: multiple human RCTs, generally positive on testosterone and cortisol. Creatine scores 5: decades of human research, exceptional safety profile.
2. Safety Signal Check. Has any peer-reviewed research raised safety concerns? If yes, how serious, and at what doses? Fadogia agrestis has a positive safety signal in the testicular toxicity rodent studies — a serious concern given the target tissue. This doesn’t prove human harm at typical supplement doses, but it’s a disqualifying concern for confident recommendation.
3. Mechanism Plausibility. Is the proposed mechanism biologically coherent and consistent with what’s known about human physiology? Fadogia scores reasonably here — LH stimulation and direct Leydig cell activation are plausible pathways. But mechanism plausibility is the weakest form of evidence. Plenty of things have plausible mechanisms and don’t work in humans.
4. Dose Translation Problem. Animal studies use doses per kilogram of body weight. Translating rat doses to human equivalents involves an allometric scaling factor (typically dividing by 6 for rat-to-human conversion using body surface area). The testosterone-producing doses in the Yakubu rat study, when scaled to human equivalents, run high. Whether typical supplement doses — usually marketed at 300-600mg per day — sit below the threshold for toxicity, at the threshold for benefit, or both, is genuinely unknown.
5. Reversibility and Monitoring. Experimenting with a compound that has an uncertain safety profile raises an obvious question: what markers get tracked, and how would anyone know if something was going wrong? For fadogia agrestis, the relevant markers would include testosterone (free and total), LH, FSH, and ideally testicular health monitoring. The testicular toxicity concern suggests that anyone choosing to experiment despite the evidence gaps should at minimum monitor LH and FSH trends over time — if LH starts to drop, that’s a warning sign of pituitary suppression or testicular dysfunction.
Running fadogia agrestis through this framework gives: low evidence quality, a serious safety signal, plausible mechanism, uncertain dose translation, and no established monitoring protocol. That combination lands on a clear “insufficient evidence for recommendation” verdict.
What Actually Works: The Boring Truth
Here’s what’s frustrating about the fadogia agrestis conversation: there are evidence-backed interventions for supporting natural testosterone production that most men are nowhere near optimizing. The focus on novel compounds is often a way of dodging the unglamorous truth that the fundamentals move the needle more than any supplement.
Resistance training — specifically compound movements, adequate volume, progressive overload — is the strongest non-pharmacological stimulus for testosterone production in men. Multiple meta-analyses confirm it. Sleep is arguably as important as training: a study published in JAMA found that reducing sleep to five hours per night for one week decreased testosterone by 10-15%. A single supplement would have to be exceptionally effective to produce those gains. Sleep is free.
Body composition matters significantly. Adipose tissue — body fat — converts testosterone to estrogen via the aromatase enzyme. Men with higher body fat have lower free testosterone and higher estrogen. Losing body fat, particularly visceral fat, is one of the most reliable ways to improve the testosterone-to-estrogen ratio.
Zinc, magnesium, and vitamin D are the three micronutrients most commonly associated with testosterone support, and deficiency in any of them correlates clearly with lower testosterone. Correcting a deficiency consistently raises levels. The complete evidence-based approach to natural testosterone optimization covers these in detail.
Against that backdrop, the marginal benefit of a novel compound with an uncertain risk profile looks a lot less attractive. Sleeping six hours, skipping leg day, carrying twenty extra pounds, deficient in vitamin D — no supplement is going to compensate for those fundamentals. And sleeping well, training hard, lean, replete in micronutrients — the incremental testosterone gain from a poorly-studied herb is probably not worth the unknown risk.
The Better Comparators: Compounds with Actual Human Data
Comparing fadogia agrestis to supplements with legitimate human evidence illustrates the evidentiary gap clearly.
Ashwagandha (KSM-66 extract): Multiple randomized controlled trials in men have found significant increases in testosterone (typically 15-20% over 8-12 weeks), reductions in cortisol (20-30%), improvements in sperm quality, and improvements in body composition and strength versus placebo. The mechanism involves cortisol reduction allowing the HPG axis to function less suppressedly. Long-term safety data is reasonable. A 4 on the evidence quality scale.
Zinc: In zinc-deficient men, supplementing to sufficiency consistently raises testosterone. Multiple controlled studies confirm this. Mechanism is clear — zinc is required as a cofactor for the enzyme that converts androstenedione to testosterone. Dose and safety are well-established. A 5 on the evidence quality scale.
Vitamin D: Vitamin D deficiency correlates with low testosterone, and supplementation in deficient men raises testosterone. A randomized controlled trial by Pilz et al. (2011) found that supplementing with 3,332 IU vitamin D daily for 12 months increased testosterone by 25% in vitamin D-deficient men versus placebo. Again — correcting a deficiency produces real gains.
Boron: A 2011 study found meaningful effects on free testosterone and sex hormone binding globulin after one week of 10mg boron supplementation. More on the boron protocol specifically, but the point here is that it has human data behind it.
Fadogia agrestis has none of these. Not a single human study. The gap between these compounds and fadogia agrestis, in terms of evidentiary standing, isn’t a gap between good evidence and decent evidence. It’s the difference between science and speculation.
Who Should (And Shouldn’t) Use Fadogia Agrestis
Given everything above, here’s an honest delineation of who might have any rational basis for taking fadogia agrestis versus who shouldn’t:
Probably not if: the evidence-backed interventions haven’t been maxed out first; there are any existing testicular or reproductive health concerns; conception is being attempted (testicular toxicity concerns are directly relevant); compounds with actual human data haven’t first been tried and properly evaluated; under 25 (developing reproductive systems); or the motivation is that a podcast made it sound exciting.
There might be a rational basis for use if: evidence-based options have been exhausted, the evidence gap is clearly understood and the risk decision is genuinely informed, relevant biomarkers (T, LH, FSH) are being monitored at baseline and throughout, doses are conservative and not cycled for long periods, and the whole thing is treated as a personal experiment with an n of 1, not a confirmed protocol.
Even in that second scenario, the honest characterization is: taking a compound that showed promising results in rats, carries a potential toxicity signal at higher doses, and has no human data, in hopes it does in a person what it did in rodents. A very different thing from what the supplement industry packaging communicates.
The Supplement Industry’s Incentive Problem
That creates an obvious incentive structure. Novel compounds with exotic names and preliminary animal data are more exciting than well-studied compounds with boring names and solid human data. Fadogia agrestis sounds more interesting than zinc. The first-mover advantage for a new compound is enormous — whoever establishes the category before competitors catches the demand wave from the inevitable media coverage.
The result: the supplement landscape is littered with compounds that cycle through hype and fade. Tribulus terrestris (multiple RCTs showed no meaningful testosterone increase in humans, despite years of marketing as a T-booster). Fenugreek (weak and inconsistent evidence). Various “test boosters” whose combined ingredients barely justify the proprietary blend labeling.
Fadogia agrestis may be different. The animal mechanism is genuinely interesting, and if human trials are ever conducted with appropriate dose finding and safety monitoring, it could turn out to be meaningfully effective and safe at the right doses. That would be excellent news. But “could turn out to be” is not “is,” and selling it as the latter is dishonest — regardless of how it’s packaged.
What People Ask About Fadogia Agrestis Testosterone
Q: How much fadogia agrestis do people typically take, and is there a safe dose?
A: Most supplements are dosed at 300-600mg of the stem extract per day. There’s no established human safe dose, because no dose-ranging or safety studies have been conducted in humans. The doses that showed testosterone increases in rats, when allometrically scaled to humans, land in the range of several hundred milligrams — which overlaps with typical supplement doses. Whether that’s below, at, or above the threshold for the testicular changes seen in rats at higher doses is genuinely unknown.
Q: If the risk is to the testes, would I notice if something was going wrong?
A: Possibly not, at least not immediately. The testicular toxicity in the rodent studies was histopathological — structural changes to tissue that wouldn’t necessarily produce noticeable symptoms in the short term. Testicular dysfunction developing over months of use would most likely show up first as changes in LH, FSH, and testosterone levels on bloodwork. Physical symptoms — testicular discomfort, changes in ejaculate volume — would be later, more serious signals.
Q: Isn’t it hypocritical to say animal studies prove risk but not benefit?
A: Not hypocritical — asymmetric risk assessment, which is appropriate here. Animal studies are insufficient to confirm benefit in humans (the track record of beneficial animal findings translating to humans is poor), but a toxicity signal in animals is worth taking seriously, because the downside risk of an undiscovered safety problem in humans is potentially irreversible. Symmetrical evidence standards aren’t required when the risk-benefit calculus itself is asymmetric.
Q: Are there any human trials being conducted on fadogia agrestis?
A: Not that are currently published or registered on ClinicalTrials.gov as of this writing. The supplement industry generally doesn’t fund clinical trials, because they can sell the product without them under current regulations. Academic interest exists but hasn’t translated to funded research yet.
Q: What should I take instead if I want to support testosterone naturally?
A: Start with the fundamentals: sleep optimization (7-9 hours), resistance training (compound movements, progressive overload), body composition (reduce excess body fat), and micronutrient sufficiency (vitamin D, zinc, magnesium). Supplement interventions with actual human evidence include correcting deficiencies in those micronutrients, ashwagandha (KSM-66 extract) for its cortisol-reducing effects, and boron if dietary intake is low. See the complete natural testosterone optimization guide for the full protocol.
Q: Lots of people in forums say they’ve had great results with fadogia. Doesn’t that count for something?
A: Forum reports are anecdotal evidence subject to severe selection bias, placebo effect, and confounding variables (plenty of people start multiple new supplements simultaneously). They count for very little scientifically. The same forums that rave about fadogia have raved about tribulus terrestris for decades — and tribulus has been thoroughly debunked in multiple RCTs. Anecdote generates hypotheses. It doesn’t confirm them.
Q: Is this the same situation as other “recently popularized” supplements that turned out to be fine?
A: The key difference is the existing safety signal. Many novel compounds have limited human data but no identified toxicity concerns — in those cases, the risk calculus is different (low evidence for benefit, low evidence for risk). Fadogia has low evidence for benefit AND a specific, relevant toxicity concern (testicular damage) from the same animal research that suggests the mechanism works. That combination is categorically different from a compound with no data either way.
The Broader Problem: How Bad Supplement Science Gets Mainstream
Fadogia agrestis is a symptom of a larger dysfunction in the health information ecosystem. The path from “rat study shows interesting result” to “millions of men taking this daily” runs through a predictable set of amplification mechanisms, each adding a layer of apparent legitimacy without adding any actual evidence.
It begins with a real study — in this case, the Yakubu 2005 paper in Asian Journal of Andrology. Real, peer-reviewed, representing a genuine finding: fadogia agrestis extract raised testosterone in rats over five days. Legitimately interesting to researchers who study androgen biology. A signal worth following up on in properly designed human research.
The first amplification happens at the content layer. Science writers, bloggers, and supplement company copywriters read the study — or more often, a press release summarizing it — and translate it into consumer-facing language. In that translation, the caveats compress. “Five-day rat study suggests mechanism worth investigating” becomes “fadogia agrestis boosts testosterone.” The passive voice and hedging of academic language gets stripped out. The finding grows more certain with each retelling.
The second amplification happens at the authority layer. A well-credentialed person with a large platform mentions the compound. The academic hedging in their original mention — which may be genuine and responsible — doesn’t survive downstream retelling. The takeaway that circulates becomes: “Stanford professor mentions fadogia agrestis for testosterone.” Whatever nuance was in the original statement detaches from its context and circulates independently as a confidence signal, minus the uncertainty that generated it.
The third amplification happens at the market layer. Supplement manufacturers recognize a demand signal and launch products within weeks. Because the Dietary Supplement Health and Education Act of 1994 doesn’t require them to demonstrate efficacy or safety before market entry, the barrier to launch is essentially zero. Product pages cite the same rat study, present it with more confidence than the original researchers did, and commission influencer endorsements to build social proof that substitutes for scientific validation.
The fourth amplification happens at the community layer. Men in training communities, optimization forums, and social media groups share their experiences. Positive outcomes — which may be placebo effect, may reflect other simultaneous interventions, or may be genuine n-of-1 responses — get shared enthusiastically. Negative outcomes or null results get posted far less frequently, creating a selection bias at the community level that mirrors publication bias in academic research. The community converges on consensus that the supplement works before a single randomized controlled trial has been conducted.
By the time Derek decides to add fadogia agrestis to his stack, the original rat study has been through all four amplification layers. He isn’t seeing the evidence. He’s seeing the end product of a social transmission process that has systematically removed uncertainty and added confidence at every step. The thing he’s evaluating bears almost no resemblance to the underlying data.
This dynamic isn’t unique to fadogia agrestis, and it’s not unique to the testosterone optimization space. The same pattern produced years of enthusiasm for tribulus terrestris (multiple RCTs eventually showed no significant testosterone effect in humans), for DHEA as a testosterone precursor (it converts to estrogen nearly as readily as to testosterone in most men), and for dozens of other compounds that cycled through hype before the evidence caught up with the marketing.
The speed of modern information flow means the cycle has compressed. In the 1990s, it might take five years for a compound to go from animal study to mainstream supplement category. Today it can happen in eighteen months. The human trial data — which takes three to five years to properly conduct and publish — can never catch up in real time with the market dynamics.
What Good Supplement Evidence Actually Looks Like
To calibrate what counts as adequate evidence, it helps to look at what the gold standard actually resembles. Ashwagandha — specifically the KSM-66 standardized root extract — is one of the better-studied botanical testosterone support compounds and illustrates what a meaningful evidence base looks like in practice.
The ashwagandha literature includes multiple independent randomized controlled trials conducted by different research groups in different countries. Wankhede et al. (2015) randomized 57 men to KSM-66 or placebo for eight weeks and found significant improvements in testosterone (approximately 15% increase), muscle strength, muscle recovery, and testosterone-to-cortisol ratio. Lopresti et al. (2019) randomized 43 overweight men to KSM-66 or placebo for eight weeks and found significant increases in testosterone and DHEA-S alongside reductions in cortisol. Multiple other trials have replicated testosterone-supportive effects across different populations: infertile men, healthy athletic men, and men with subclinical hypogonadism.
The mechanism — primarily through reducing cortisol, which suppresses the HPG axis via cortisol’s inhibitory effects on GnRH — is biologically coherent and consistent with the experimental findings. Cortisol and testosterone have a well-characterized antagonistic relationship: chronically elevated cortisol suppresses LH, reduces testosterone production, and promotes muscle catabolism. Reducing cortisol lets the HPG axis operate more freely. This mechanism is well-established, not hypothetical.
The safety profile has been characterized across multiple studies, with reported adverse events generally mild and uncommon. Long-term safety data exists from populations using ashwagandha traditionally for centuries. The compound has been used in Ayurvedic medicine for over 3,000 years, providing a historical safety signal that animal studies alone can’t.
That’s what a well-studied botanical testosterone support compound looks like. Multiple independent RCTs. Replicated findings across different research groups. Characterized mechanism with strong theoretical foundation. Established safety profile across multiple study types and time horizons. Ashwagandha isn’t perfect science — the trials are generally small by pharmaceutical standards, and effect sizes are modest — but it represents a fundamentally different evidentiary position than fadogia agrestis, which has none of these features.
The comparison isn’t made to disparage fadogia agrestis or to suggest it can never develop a similar evidence base. It’s made to illustrate that the distance between where fadogia agrestis stands today and where ashwagandha stands today represents roughly a decade of additional research and multiple independent confirmations. Treating them as equivalently supported compounds because both are “natural” and both have been discussed on popular podcasts is a category error.
For the complete framework on which natural compounds have genuine evidence behind them and how to layer them intelligently, see the natural testosterone optimization guide. For the ashwagandha-specific evidence in depth, the ashwagandha testosterone evidence review covers the clinical literature in full detail.
How to Think About Your Own Risk Tolerance
Ultimately, supplement decisions are personal risk assessments. There’s no universally correct answer to “should I take fadogia agrestis,” because the answer depends on individual values, risk tolerance, current hormonal status, and what someone is willing to do in terms of monitoring.
Take a 25-year-old man who’s already optimized his sleep, training, and diet — corrected any micronutrient deficiencies, run a full hormone panel showing normal function across all markers. He might reasonably decide that experimenting with fadogia agrestis at conservative doses with regular monitoring represents an acceptable personal risk. He understands the evidence gap. He understands the toxicity signal. He’s going in with eyes open, monitoring appropriate biomarkers, ready to stop at the first concerning signal. An informed adult making an informed personal decision.
Compare that to a 25-year-old who adds fadogia agrestis to his stack because a forum post said it works, who’s never had a hormone panel, who’s also taking multiple other supplements simultaneously, who doesn’t know what biomarkers to monitor, and doesn’t know the difference between a rat study and a human RCT. A completely different situation. Not an informed decision. A decision made in the dark, because the information he’s been given systematically obscures what he doesn’t know.
The goal here is to make sure anyone who decides to use fadogia agrestis lands in the first category rather than the second. Know the evidence. Know the safety signals. Know what to monitor. Make the decision with full information about what’s known and what isn’t. And if the monitoring isn’t going to happen, or the evidence-backed interventions haven’t been maxed out yet, the rational choice is to wait.
Science eventually catches up with the market. In five years, there may be randomized controlled trials on fadogia agrestis that settle the question. If those trials show it’s effective and safe at specific doses, that will be genuinely useful information worth acting on. Until then, the absence of evidence is not evidence of safety, and the enthusiasm of forum communities is not a substitute for clinical research.
Fadogia Agrestis Testosterone: What Readers Ask (Continued)
Q: What about combining fadogia agrestis with tongkat ali, which is commonly sold together?
A: Tongkat ali (Eurycoma longifolia) has a substantially better human evidence base than fadogia agrestis. Multiple randomized controlled trials have found that standardized tongkat ali extract (particularly the 200:1 eurycomanone-standardized form) improves testosterone levels, sexual function, and stress hormone profiles in men. For a botanical LH stimulator, tongkat ali is the better-evidenced option — it has the human data fadogia lacks. The frequent pairing of the two in supplement products appears driven by marketing synergy (“as discussed by Huberman”) rather than evidence that the combination beats tongkat ali alone.
Q: Should I avoid fadogia agrestis entirely if I’m already on testosterone replacement therapy?
A: The main reason men take fadogia agrestis is to support natural testosterone production by stimulating the HPG axis. TRT suppresses the HPG axis entirely — the hypothalamus and pituitary are no longer driving LH production once exogenous testosterone is in the picture. In that context, a compound that works by stimulating LH is acting on a pathway TRT has already bypassed. The mechanism for benefit doesn’t operate the same way. On top of that, the testicular concerns become more relevant if the testes are already in a suppressed state from TRT and a compound that may stress testicular tissue gets added on. Men on TRT have even less justification for fadogia agrestis than men with natural testosterone production.
Q: If the research eventually comes out positive for fadogia agrestis, what would the ideal protocol look like?
A: Hypothetically, if well-designed human trials established a safe and effective dose, a reasonable protocol would likely involve: a defined dose range (established through dose-finding studies, not extrapolated from rats), cycling rather than continuous use to prevent potential downregulation or tissue stress, baseline and follow-up hormone panels including LH and FSH to confirm the HPG axis is responding appropriately, and avoidance during periods when testicular function is especially important (fertility treatment, recovery from illness). The specifics would need to come from actual trial data. Until that data exists, even the hypothetical protocol is premature to design in detail.
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map